The combination of veliparib, carboplatin, and paclitaxel also demonstrated superior PFS versus placebo/carboplatin/paclitaxel in the Phase III BROCADE3 trial that included 509 patients with gBRCA1/2 and HER2-negative advanced breast cancer. The gene discussed is ERBB2; the disease is breast cancer.